Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 3195 of 5804
-
Experimental drug offers hope for cancer patients with depleted immune cells
Disease control AVAILABLEThis is a protocol for expanded access use of nogapendekin-alfa inbakicept (NAI) in participants with lymphopenia induced by chemotherapy, immunotherapy, and/or radiation therapy who may benefit from its use, and who are ineligible to participate in a clinical trial using NAI. Th…
Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New imaging tool helps surgeons pinpoint hidden parathyroid tumors
Diagnosis AVAILABLEThis expanded access protocol is proposed to allow University of California San Francisco (UCSF) patients additional access to 18F-fluorocholine (FCH) Positron Emission Tomography (PET) imaging for localization of parathyroid adenomas.
Sponsor: Thomas Hope • Aim: Diagnosis
Last updated Jun 27, 2026 07:55 UTC
-
Parkinson's patients get early access to experimental drug tavapadon
Disease control AVAILABLEThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to tavapadon prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential bene…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Last-Resort treatment opens for rare swallowing disorder
Disease control NO_LONGER_AVAILABLEThis expanded access program is an open-label, single-arm design where consenting patients may participate up until APT-1011 is commercially available in the relevant regions or the protocol is terminated by the Sponsor.
Sponsor: Ellodi Pharmaceuticals, LP • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug access for Hard-to-Treat blood cancer patients
Disease control NO_LONGER_AVAILABLEThe purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Desperate patients get early access to promising drug
Disease control AVAILABLEThe purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Desperate patients get early access to experimental drug ianalumab
Disease control AVAILABLEThe purpose of this registration is to list Managed Access Programs (MAPs) related to VAY736, ianalumab
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Desperate breast cancer patients get access to promising drug through special program
Disease control AVAILABLEThe purpose of this registration is to list Managed Access Programs (MAPs) related to LEE011, Ribociclib
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug access for patients in need
Disease control AVAILABLEThis is an expanded access designed to provide access to Mezigdomide for eligible participants.
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Last-Resort drug made available for Tough-to-Treat melanoma
Disease control NO_LONGER_AVAILABLEProvide Compassionate Use of Vidutolimob
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Desperate patients get early access to experimental muscle cell therapy
Disease control TEMPORARILY_NOT_AVAILABLEThis is an expanded access program (EAP) for eligible participants designed to provide access to autologous muscle derived cells (AMDCs). Treating physicians may submit requests for expanded access to Cook MyoSite's investigational product by email to MYO-ExpandedAccess@CookMyoSi…
Sponsor: Cook MyoSite • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New heart device made available through FDA expanded access
Disease control AVAILABLEOcclutech AFR use allowed per FDA's Expanded Access program.
Sponsor: Occlutech International AB • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New treatment option available through expanded access
Disease control AVAILABLEThis is an expanded access designed to provide access to Iberdomide for eligible participants.
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Last-Resort drug access for rare tumor patients
Disease control AVAILABLEThis program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Last-Resort leukemia drug made available to 29 patients
Disease control TEMPORARILY_NOT_AVAILABLEThe main study (CLR\_15\_03) was terminated prematurely for non-safety reasons due to changes in the clinical treatment landscape and evolving regulatory considerations. To ensure continuity of care, post-trial access to vodobatinib was initiated in January 2024 for subjects who,…
Sponsor: Sun Pharma Advanced Research Company Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Epilepsy patients get continued access to brivaracetam through compassionate program
Disease control NO_LONGER_AVAILABLEThis Compassionate Use Program (CUP) is setup to provide study patients with continuous access to Brivaracetam (BRV) for the time period between closures of the long-term follow up studies N01125, N01199, N01372, N01379, and N01315 and when BRV is commercially available.
Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for heart patients: pelacarsen available through special program
Disease control AVAILABLEThe purpose of this registration is to list Managed Access Programs (MAPs) related to TQJ230, pelacarsen
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug made available for patients with no other options
Disease control AVAILABLERequests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only …
Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental device aims to tame disease without drugs
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Compassionate access program offers continued treatment for immune deficiency
Disease control AVAILABLEThe expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. This study will provide access to TAK-881 for participants with PIDD who have completed study TAK-881-3002 \[NCT06076642\], who continue to derive clinical benefit from m…
Sponsor: Takeda • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC